<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01835353</url>
  </required_header>
  <id_info>
    <org_study_id>PATRASCARDIOLOGY-13</org_study_id>
    <nct_id>NCT01835353</nct_id>
  </id_info>
  <brief_title>High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)</brief_title>
  <official_title>High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, non-randomized, controlled study in 2 sequential groups
      of P2Y12 inhibitor-naive consecutive STEMI patients undergoing primary PCI. Following aspirin
      325 mg LD, patients will receive 60 mg or 100 mg of prasugrel, respectively. Platelet
      reactivity (PR)will be assessed at Hour 0 (before prasugrel's administration immediately
      prior to PCI) and at Hours 0.5, 1, 2, 4 thereafter. Platelet function testing (in PRU) will
      be performed with the VerifyNow (Accumetrics Inc., San Diego, CA, USA) P2Y12 function assay.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity in Platelet reactivity units (PRU) at Hour 2</measure>
    <time_frame>2 hours</time_frame>
    <description>Platelet reactivity in Platelet reactivity units (PRU) 2 hours post randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity in platelet reactivity units (PRU)at hour 1</measure>
    <time_frame>1 hour</time_frame>
    <description>Platelet reactivity in platelet reactivity units (PRU)1 hour post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity in platelet reactivity units (PRU)at hour 0.5</measure>
    <time_frame>0.5 hours</time_frame>
    <description>Platelet reactivity in platelet reactivity units (PRU)0.5 hour post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity in platelet reactivity units (PRU)at hour 4</measure>
    <time_frame>4 hours</time_frame>
    <description>Platelet reactivity in platelet reactivity units (PRU)4 hours post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity rate (208 PRU threshold) at 0.5 hour</measure>
    <time_frame>0.5 hour</time_frame>
    <description>High platelet reactivity rate (208 PRU threshold) 0.5 hour post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity rate (208 PRU threshold) at 1 hour</measure>
    <time_frame>1 hour</time_frame>
    <description>High platelet reactivity rate (208 PRU threshold) 1 hour post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity rate (208 PRU threshold) at 2 hour</measure>
    <time_frame>2 hours</time_frame>
    <description>High platelet reactivity rate (208 PRU threshold) 2 hours post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity rate (208 PRU threshold) at 4 hour</measure>
    <time_frame>4 hours</time_frame>
    <description>High platelet reactivity rate (208 PRU threshold) 4 hours post randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Platelet Reactivity</condition>
  <arm_group>
    <arm_group_label>Prasugrel 100mg loading dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel 100mg loading dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel 60mg loading dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel 100mg loading dose</intervention_name>
    <arm_group_label>Prasugrel 100mg loading dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel 60mg loading dose</intervention_name>
    <description>Prasugrel 60mg loading dose</description>
    <arm_group_label>Prasugrel 60mg loading dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ST elevation myocardial infarction

          -  Pain onset &lt;12 hours

          -  Age &gt;18 and &lt;75 years

          -  Written informed consent

        Exclusion Criteria:

          -  history of stroke/transient ischemic attack

          -  oral anticoagulation

          -  hemodynamic instability

          -  platelet count &lt;100000/Î¼L

          -  hematocrit &lt;30%

          -  creatinine clearance &lt;30 ml/min

          -  severe hepatic dysfunction

          -  active bleeding

          -  weight &lt;60 Kg

          -  periprocedural IIb/IIIa inhibitor administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dimitrios Alexopoulos</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2013</study_first_submitted>
  <study_first_submitted_qc>April 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2013</study_first_posted>
  <last_update_submitted>September 20, 2013</last_update_submitted>
  <last_update_submitted_qc>September 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>prasugrel</keyword>
  <keyword>ST elevation myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

